Skip to content

Characterization of gut microbiota in patients with heart failure with preserved ejection fraction

Characterization of gut microbiota in patients with heart failure with preserved ejection fraction (GUMPTION study)

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050121
Enrollment
Unknown
Registered
2021-08-16
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Control group:None
Case group:None

Sponsors

Dushu Lake Hospital Affiliated to Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. HFpEF group (HFpEF patients treated at Suzhou Dushu Lake Hospital): (1) Meet the diagnostic criteria for HFpEF in the ''China Heart Failure Diagnosis and Treatment Guidelines'' formulated in 2018; (2) The patient gave informed consent and signed the informed consent form. 2. Control group (those who underwent health checkup at Suzhou Dushuhu Hospital): (1) All people have no previous cardiovascular diseases such as hypertension, coronary heart disease, cardiomyopathy, pericardial disease, heart valve disease, etc., and heart failure caused by various causes is excluded according to the diagnostic criteria of heart failure; (2) Informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with acute heart failure, acute pericarditis, acute myocarditis, and congenital heart disease; 2. Patients who received oral or intravenous antibiotics within three months of the stool sampling day; 3. Patients with topical antibiotics on the skin within one month of the stool sampling day; 4. Patients who ingested probiotic preparations within three months of the stool sampling day; 5. Patients with intestinal diseases (such as intestinal polyps, inflammatory bowel disease, irritable bowel syndrome, etc.) or patients with a history of gastrointestinal surgery; 6. Patients with other non-cardiovascular diseases (such as malignant tumors) that have been confirmed to change the intestinal flora.

Design outcomes

Primary

MeasureTime frame
Alpha diversity;Beta diversity;The species composition of intestinal flora;Rank-abundance distribution curves;VEEN picture;

Countries

China

Contacts

Public ContactJiang Yufeng

Dushu Lake Hospital Affiliated to Soochow University

yufeng_jiang@hotmail.com+86 18862330234

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026